A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
← catalyst calendarNCT07662213 · readout in 643 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
1,200estimated
Sites
201
Countries
Argentina, Australia, Brazil +12
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-06 | actual | When the study began enrolling |
| Primary completion | 2028-05-23 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-05-23 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Type 2 Diabetes Mellitus
Interventions
- Drug: Elecoglipron
- Drug: Semaglutide
Primary outcome
what the primary-completion date above is the date OFChange from baseline in Hemoglobin A1c (HbA1c)
measured Baseline to Week 52
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed